Table 2 Renal function and biochemical data of patients with β-Thalassemia Major and their subgroups based on chelation treatment in the current and previous study

Gender (M:F)

(13:13)

(5:5)

(18:18)

(13:16)

Age

19.4 ± 9.3

24.8 ± 10.2

20.9 ± 9.5

14 ± 8.1

Serum Cr (mg/dl)

(0.6–1.1)

0.64 ± 0.11

0.6 ± 0.14

0.63 ± 0.12

0.54 ± 0.09

Serum sodium (meq/l)

(135–145)

137.6 ± 1.7

137.1 ± 2.2

137 ± 1.8

139 ± 2

Serum potassium (meq/l)

(3.5–5.5)

4.12 ± 0.3

4.17 ± 0.19

4.12 ± 0.2

4.25 ± 4.6

Serum uric acid (mg/dl)

(2.5–7.5)

4.3 ± 1.2

4.3 ± 1.2

4.54 ± 1.2

4.3 ± 0.9

GFR (ml/min per 1.73 m²)

(> 60)

100.9 ± 17

114 ± 22

104.6 ± 19

109.7 ± 23.2

eGFR

(ml/min per 1.73 m²)

113.2 ± 21

124.8 ± 26

116.4 ± 23

113.5 ± 26

uNAG (IU/l)

(< 12)

10.42 ± 6.1*

5.33 ± 2.7*

9.07 ± 5.8

10.76 ± 6.7

Abnormal uNAG

(8/26) 30.7%

(1/10) 10%

(9/36) 25%

(8/29) 27.5%

Patients with ProtU> 150 mg/d or equivalent prot/ Cr ratio

(2/26) 7.7%

(2/10) 20%

(4/36) 11.1%

Urine Ca/Cr

(< 0.14)

0.229 ± 0.2

0.173 ± 0.1

0.21 ± 0.2

0.09 ± 0.1**

Abnormal Urine Ca/Cr

(8/26) 30.7%

(2/10) 20%

(10/36) 27.8%

(2/29) 6.9%

FeNa (%)

0.84 ± 0.245

0.70 ± 0.33

0.8 ± 0.43

0.94 ± 0.61

FeK (%)

(4–16)

13.2 ± 8.3

13.6 ± 8.9

13.3 ± 8.3

16 ± 8.3

UAE (mg/dl GFR)

(< 0.56)

0.7 ± 0.24

0.56 ± 0.19

0.66 ± 0.23

0.75 ± 0.24

Abnormal UAE

(18/26) 69.2%

(5/10) 50%

(23/36) 63.8%

(21/29) 72.%

TmP/GFR (mg/dl)

(3–5)

4.63 ± 0.68

4.75 ± 0.95

4.67 ± 0.75

4.89 ± 1.15

Urine osmolality (mosmol/kg)

(50–1200)

678.2 ± 188

705 ± 222

685.7 ± 193

757 ± 170